Advertisement
New Zealand markets close in 34 minutes
  • NZX 50

    11,711.18
    -153.71 (-1.29%)
     
  • NZD/USD

    0.6129
    -0.0015 (-0.25%)
     
  • NZD/EUR

    0.5719
    -0.0014 (-0.24%)
     
  • ALL ORDS

    7,966.20
    -8.60 (-0.11%)
     
  • ASX 200

    7,723.00
    -1.30 (-0.02%)
     
  • OIL

    78.15
    -0.30 (-0.38%)
     
  • GOLD

    2,338.90
    -10.20 (-0.43%)
     
  • NASDAQ

    19,659.80
    +82.90 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.68 (-1.44%)
     
  • Hang Seng

    17,978.30
    +36.52 (+0.20%)
     
  • NIKKEI 225

    38,004.93
    -809.63 (-2.09%)
     
  • NZD/JPY

    96.4160
    -0.2360 (-0.24%)
     

Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company

Key Insights

  • Institutions' substantial holdings in Biogen implies that they have significant influence over the company's share price

  • 51% of the business is held by the top 16 shareholders

  • Recent sales by insiders

If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. With 87% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.

ADVERTISEMENT

In the chart below, we zoom in on the different ownership groups of Biogen.

Check out our latest analysis for Biogen

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Biogen?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Biogen does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Biogen's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Biogen is not owned by hedge funds. PRIMECAP Management Company is currently the company's largest shareholder with 11% of shares outstanding. For context, the second largest shareholder holds about 9.9% of the shares outstanding, followed by an ownership of 8.3% by the third-largest shareholder.

A closer look at our ownership figures suggests that the top 16 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Biogen

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our information suggests that Biogen Inc. insiders own under 1% of the company. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own US$99m worth of shares (at current prices). Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 12% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Biogen you should know about.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here